Opdivo with Yervoy for renal cell carcinoma – pro
It was recently FDA approved. The Opdivo + low-dose Yervoy combination showed a significantly superior overall survival versus sunitinib in intermediate- and poor-risk advanced renal cell carcinoma, including a survival benefit regardless of PD-L1 expression. In the CheckMate -214 trial, which used dosing optimized for advanced renal cell carcinoma, Opdivo + Yervoy was associated with fewer overall Grade 3 or 4 adverse reactions than sunitinib.
Opdivo Prescribing Information. Opdivo U.S. Product Information. Last updated: April 2018. Princeton, NJ: Bristol-Myers Squibb Company.
Robert J. Motzer, M.D., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell N Engl J Med 2018; 378:1277-1290